Kodiak Sciences Inc KOD

NAS: KOD | ISIN: US50015M1099   1/05/2024
3,530 USD (+9,97%)
(+9,97%)   1/05/2024

28 maart 2024 · Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results · Persbericht

26 maart 2024 · Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 · Persbericht

30 januari 2024 · Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting · Persbericht

4 januari 2024 · Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

6 november 2023 · Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission · Persbericht

2 november 2023 · Kodiak Sciences Announces First Time Presentation Of Primary Endpoint Data From Tarcocimab Tedromer Phase 3 Glow Study In Patients With Diabetic Retinopathy At American Academy Of Ophthalmology Annual Meeting · Persbericht

11 oktober 2023 · Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society · Persbericht

8 september 2023 · Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference · Persbericht

7 september 2023 · New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion · Persbericht

14 augustus 2023 · Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

24 juli 2023 · Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program · Persbericht

30 mei 2023 · Kodiak Sciences to Present at Upcoming Investor Conferences · Persbericht

15 mei 2023 · Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

21 april 2023 · Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting · Persbericht

3 april 2023 · Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases · Persbericht

28 maart 2023 · Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights · Persbericht

9 februari 2023 · Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting · Persbericht

4 januari 2023 · Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

16 november 2022 · Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference · Persbericht

9 november 2022 · Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights · Persbericht

Mijn selecties